After hours:
Chart Events
Performance Outlook
| Previous Close | 6.50 |
| Open | 6.70 |
| Bid | 6.60 x 1800 |
| Ask | 7.00 x 1400 |
| Day's Range | 6.53 - 6.96 |
| 52 Week Range | 5.47 - 12.79 |
| Volume | |
| Avg. Volume | 429,296 |
| Market Cap | 1.529B |
| Beta (5Y Monthly) | 2.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.53 |
| Earnings Date | Nov 14, 2023 - Nov 20, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.92 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CVAC
Related Research
- CureVac N.V.Analyst Report: CureVac N.V.CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac’s first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company’s other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.RatingFair ValueEconomic Moat4 days agoMorningstar
Motley FoolWhy CureVac Stock Plunged Today
Shares of CureVac (NASDAQ: CVAC) were down 9.1% as of 2:45 p.m. ET Thursday after a German court temporarily suspended the biopharmaceutical company's patent trial against BioNTech (NASDAQ: BNTX). CureVac previously failed to develop a successful COVID-19 vaccine during the pandemic, opting instead to focus on potential second-generation vaccines in partnership with GlaxoSmithKline. BioNTech, by contrast, generated tens of billions of dollars in annual revenue from its successful mRNA vaccines developed in partnership with Pfizer.
ACCESSWIRECureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
Regional Court Düsseldorf postpones infringement ruling on four intellectual property rights in lawsuit filed by CureVac against BioNTechRuling on infringement to be provided latest once the validity of the intellectual property rights in suit has ...
- Reuters
CORRECTED-German court suspends mRNA patent trial against BioNTech
A German court on Thursday suspended a patent trial against BioNTech over the use of mRNA technology in the COVID-19 vaccine developed by the German company together with its U.S. partner Pfizer. The Duesseldorf regional court said it needed further clarification and suspended the case, brought by BioNTech competitor CureVac, pending decisions by the German and the European patent offices on a legal challenge filed by BioNTech. A separate patent infringement case brought by CureVac was previously suspended by the Duesseldorf court because a higher court first needs to review that patent's validity.
